<DOC>
	<DOCNO>NCT00476164</DOCNO>
	<brief_summary>Purpose clinical trial ; Evaluate effectiveness rituximab C4d+ CAN Primary objective ; To determine whether anti-CD20 therapy stabilize improve renal function and/or proteinuria patient C4d+ , chronic ( humoral ) rejection standard therapeutic approach fail . Secondary objective ( ) ; - To compare patient graft survival control rituximab-treated group - To evaluate adverse effect profile rituximab group - To correlate change circulate B cell number , anti-HLA non-HLA Ab profile titre response standard therapy / rituximab - To correlate change T cell responsiveness alloantigens response standard therapy / rituximab Study Design ; Prospective , randomise , two arm , open-labeled Study Endpoints ; Primary - Rate deterioration renal function , define slope reciprocal creatinine plot , sample take 3-5 month post-randomisation . - Change degree proteinuria , present , 3-5 month post-randomisation 2˚ endpoint , determine 3-5 month post-randomisation 1 , 2 3 year post-recruitment ; - Rate deterioration renal function , define slope reciprocal creatinine plot , determine analysis sample take since previous assessment . - Patient survival - Graft survival - Incidence culture positive infection - Incidence malignancy - Degree proteinuria - Changes circulate CD20+ cell peripheral blood - Changes anti-graft Ab titre , ( measure every 3 month ) - Changes T cell responsiveness alloantigens ( measure every 3 month ) . Sample Size ; 15 patient randomised arm ( i.e . 30 patient randomise ) . Up 120 patient need enrol study . In addition , participant receive live donor kidney , donor approach provide 5 sample blood help vitro analysis . Summary eligibility criterion ; - Male female renal allograft recipient 18-70 year age - 6/12 post-transplantation - Either deteriorate allograft function reciprocal creatinine plot significant proteinuria . - C4d+/- CAN renal allograft biopsy Investigational medicinal product dosage ; Rituximab , 1g day 0 1g day 14 Active comparator product ( ) ; None Route ( ) administration ; Intravenous infusion Maximum duration treatment subject ; 14 day rituximab . The treatment arm study , include optimisation period , formal run-in post-randomisation phase last 10 month post-recruitment . Procedures ; Screening &amp; enrollment . Potentially eligible patient identify screen renal allograft biopsy perform 'creeping creatinine ' and/or proteinuria . Recruitment inform consent prior enrollment . Procedures ; Baseline . In addition routine test , blood anti-HLA non-HLA antibody analysis peripheral blood mononuclear cell ( PBMC ) purification . Procedures ; Treatment period . 3 month run-in period optimal conventional immunosuppressive therapy , precede 2 month allow tailored-optimization . Patients review least six time normal transplant clinic appointment routine blood biochemistry , full blood count urine analysis . At end run-in period , blood take anti-graft antibody analysis PBMC purification . Those patient allograft function stabilises and/or proteinuria improves normal transplant clinic follow-up appointment blood take anti-graft antibody PBMC purification every 3 month 3 year . Those continue deterioration either allograft function persist worsen proteinuria randomise . These patient review normal transplant clinic appointment primary end-point need least 6 routine blood biochemistry , full blood count urine analysis final 3 month period , post-randomisation . At primary end-point , blood take anti-graft antibody analysis PBMC . Procedures ; End Study . •Follow continue 3 year , blood take anti-graft antibody analysis PBMC purification every three month Procedures safety monitor trial ; Regular patient interview examination , routine haematological biochemical analysis . Serious adverse event report forwarded sponsor , MHRA , LREC Roche appropriate The WLRATC transplant research committee discuss trial safety concern regular three monthly meeting . Data review 30 also 60 people enrol . Criteria withdrawal patient safety ground ; Serious adverse effect relate rituximab infusion</brief_summary>
	<brief_title>Study Rituximab Treat Chronic Renal Transplant Rejection</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>Functioning kidney allograft ( estimate ( e ) GFR MDRD &gt; 20 ) &gt; 6/12 posttransplantation Deteriorating allograft function define linear regression reciprocal creatinine plot . Deterioration define negative slope least precede 3 month ( least 6 creatinines include ) adjust r2 &gt; 0.35 p value ≤0.05 compare horizontal baseline . Deterioration confirm reduction CockcroftGault ( CG ) eGFR period ( exclude increase body mass cause negative slope reciprocal creatinine plot ) OR significant proteinuria assess urine protein/creatinine ratio ≥50 CAN , Banff '97 criterion , and/or transplant glomerulopathy renal allograft biopsy perform within 6/12 enrolment Diffuse , linear C4d deposition least 25 % peritubular capillary ( PTC ) and/or glomerular EC renal transplant biopsy assess immunoperoxidase &gt; 50 % PTC ( alone ) assess immunofluorescence OR PTCitis OR glomerulitis combine PTC/g score ≥2 . Ages 18 year age Suspicion pregnancy confirm positive HCG pregnancy test Untreated ureteric obstruction ultrasound allograft History acute allograft rejection precede 3/12 History MI precede 3/12 History malignancy previous 5 year ( exclude tumours limited skin ) Symptomatic IHD Recipient simultaneous pancreas/kidney transplant Recipient ABOincompatible kidney Recipient underwent HLA desensitisation procedure prior transplantation Evidence , examination renal allograft biopsy specimen , recurrent denovo disease ( except IgA deposition absence mesangial proliferation ) Evidence , examination renal allograft biopsy specimen , CNI toxicity IF ACCOMPANIED mostly supratherapeutic CNI trough level 6 month period precede biopsy . Documented allergy mouse chimeric human/mouse proteins HepBsAg+ , HepBcAb+ , HCV Ab+ HIV+ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic allograft nephropathy</keyword>
	<keyword>C4d</keyword>
	<keyword>Anti-CD20</keyword>
	<keyword>B cell</keyword>
	<keyword>Antibody</keyword>
</DOC>